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Abstract
Objective/Aim One of the factors limiting the long-term
success of glaucoma drainage devices and traditional
filtering surgery is the tendency of bleb encapsulation.
Glaucoma shunts present an opportunity of introducing
drug-eluting mechanisms for a lasting exposure of the bleb to
anti-proliferative substances. The aim of this in vitro study was
to investigate the effects of short- and long-term exposure of
primary cultures of human Tenon's fibroblasts to different
concentrations of paclitaxel on cell proliferation, migration,
collagen production and cytotoxicity, in order to evaluate the
suitability of the drug for the use in such a device.
Materials/Methods Seven individual primary cultures of
human Tenon's fibroblasts were observed over the course of
1 week after administering paclitaxel concentrations vary-
ing from 10−9 mol/l to 10−6 mol/l for either 1 hour or
continuously. Relative cell count and migration across a
cell-free area introduced by scratching through a confluent
cell layer were determined every 24 hours, using photo-
micrographs of the cells for each concentration and
exposure time. Soluble collagen concentration in the cell
culture medium was determined using a Sircol collagen
assay 72 hours after paclitaxel exposure. Cytotoxicity of the
compound was assessed by flow cytometry using dual
staining with annexin V-FITC and propidium iodide.
Results Paclitaxel dose-dependently inhibited both prolif-
eration and migration of the cells. Cell count was reduced at
all concentrations and both exposure times (p=0.001);
similarly, all but two concentrations of paclitaxel caused a
significant reduction of cell migration (p<0.001). This may
be explained in part by the dose- and time-dependent
induction of apoptosis in up to 23.7% of the cells (maximal
effect at 10−6 mol/l, 7 days after exposure). Collagen
production was significantly reduced at all concentrations
and at both exposure times. However, no statistically
significant difference was observed between any of the
concentrations, indicating that this inhibition may be an
indirect effect.
Conclusion Paclitaxel may be a useful addition to the
repertoire of anti-proliferative substances currently in use in
glaucoma filtering surgery and shunt implantation. Further
studies of the compound and its effects on Tenon's
fibroblasts as well as other ocular tissues are warranted.
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drainage device . Paclitaxel . Proliferation .Migration .
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Introduction
Scar formation following filtering glaucoma surgery is one
of the most difficult problems limiting the lasting success
of this type of intervention. Despite the use of anti-
proliferative substances such as mitomycin C (MMC) or
the anti-metabolite 5-fluorouracil (5-FU), the intermediate
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and long-term success rates of trabeculectomies in numer-
ous studies, using a variety of different doses and exposure
times, do not exceed 55–73% [1, 2] for complete and 73–
91% [1, 3] for qualified success. Although the mechanisms
involved in scar tissue formation after filtering surgery are
not fully understood, it is evident that excessive prolifera-
tion of fibroblasts from Tenon's capsule and conjunctiva,
transdifferentiation of these fibroblasts into myofibroblasts,
as well as uncontrolled production of extracellular matrix
(ECM) play a major role in the process. Factors contributing
to the problem include inflammation, increased levels of
transforming growth factor beta2 (TGF-beta2) in the drained
aqueous humor [4, 5] and an increased expression of TGF-
beta type II receptor in the fibroblasts of the bleb [6].
An even worse situation is seen in cases where glaucoma
drainage devices (GDD) such as the classic Molteno or
Baerveldt devices or the valved Ahmed device are used.
Rapid encapsulation within months after initial implanta-
tion occurs in up to 30% of pediatric patients (own
unpublished data), necessitating follow-up surgery to
remove the fibrous capsules. This may be due to continuous
sub-clinical inflammation caused by the base plates of the
devices which results in increased scar tissue formation.
The inflammatory response has been linked to the bioma-
terial of the devices [7, 8], as well as other physical
properties such as size and shape of the endplates [9, 10].
Furthermore, studies have shown that MMC does not
improve the long-term outcome of GDD-implantation
[11–14]. Thus, new and more effective ways to inhibit
excessive scar formation are needed.
Paclitaxel is a compound from taxus brevifolia that is
used successfully in the treatment of malignant solid tumors
such as ovarian and breast cancer as well as non small cell
lung cancer (NSCLC) [15]. Paclitaxel binds to and
stabilizes microtubules of the mitotic spindle, and thereby
inhibits cell division. It induces apoptosis in these tumor
cells by mechanisms involving microtubule-associated
caspases. Paclitaxel has also been shown to inhibit the
growth of fibroblasts at low concentrations in various
fibrosis models, in part by interfering with TGF-beta
signaling [16, 17].
One interesting application of the substance is its
extended release from coated coronary stents, which has
led to decreased rates of re-stenosis of coronary arteries
after intervention [18]. We wanted to explore the possibility
of using paclitaxel as an anti-proliferative compound for a
drug-eluting glaucoma drainage device. The aim of this
study therefore was to investigate whether extended
exposure of human Tenon's fibroblasts (HTF) to various
low concentrations of paclitaxel can inhibit proliferation,
migration and collagen production of these cells in vitro, to
assess potential cytotoxicity and compare all of the effects
to those seen after an only brief exposure to the compound.
Materials and methods
Human Tenon's fibroblast cell culture
Small samples of approximately 1–2 mm3 of Tenon's
capsule were procured sterilely from donor eyes of the local
eye bank no more than 5 hours post mortem, if the donors
had consented to the scientific use of excess material. The
tissue samples were transferred into a standard 60 mm cell
culture dish, covered with a 20 mm glass cover slip, supplied
with culture medium (Dulbecco’s modified Eagle medium
(DMEM), supplemented with 10% fetal calf serum (FCS)
and 1% penicillin/streptomycin) and then placed in a 37°C,
5% CO2-containing incubator. After 1–2 weeks, when cells
had grown out about 1.5 cm from the tissue sample, cells
were passaged into 25 cm2 culture flasks using the Trypsin/
EDTA method. This was considered passage one. All further
passages followed the same method, dividing the cells into
three equal fractions each time. Seven individual cell lines
were established in this fashion, dubbed HTF-1 to HTF-7.
Identity of the cells was confirmed immunocytologically by
staining for CD90, using the commercially available mono-
clonal antibody AS02 (Dianova, Germany). For each
experimental series, cells from all cell lines, each from the
same passage, were used. Overall, only passages four to six
were utilized. Tissue procurement and all experiments
adhered to the Declaration of Helsinki.
Proliferation
HTF cells were seeded into 12-well plates at a cell density
of 2,500 cells per well. Over the course of 1 week, four
photographs of the cells were taken at predefined spots of
each well every 24 hours, using a standard CCD camera
attached to an inverted stage microscope (Leica DM IL,
Wetzlar, Germany). The cells were counted using ImageJ
(v.1.41); the mean number of cells per photograph on each
day was used as one data point. Cell count of HTF cells
incubated with medium plus vehicle (0.1% ethanol) was
compared to that of cells treated with different concen-
trations of Paclitaxel (Sigma-Aldrich, Steinheim, Germany;
range 10−9 mol/l to 10−6 mol/l), which were exposed to the
compound either for 1 hour or continuously during the
entire time of observation.
Scratch-migration assays
In order to determine the migratory activity of HTF cells
treated with paclitaxel, the cells were seeded into 24-well
plates and allowed to grow to confluence. Using a standard
pipette tip, a scratch was then introduced through the centre
of each well. The detached cells were washed off with PBS,
leaving a clean, cell-free area of 550–600 µm width in each
198 Graefes Arch Clin Exp Ophthalmol (2010) 248:197–206
well. Cell culture medium containing varying concentra-
tions of Paclitaxel (10−9 mol/l to 10−6 mol/l) or vehicle
alone was added to the wells. The width of the scratch over
the course of 1 week was determined using photographs
taken every 24 hours, employing the ImageJ software.
Collagen assays
The colorimetric Sircol soluble collagen assay (Biocolor
Ltd., UK) uses a dye that specifically binds to the native
triple helix structure of collagen. This dye is added in
excess amounts to a collagen-containing solution (e.g.
tissue homogenate or supernatant cell culture medium)
and thoroughly mixed. Through centrifugation of the dye/
sample mix (10,000 g for 10 minutes), a pellet of collagen
with bound dye forms; the supernatant with unbound dye is
discarded. The pellet (and with it the dye) is then dissolved
in an acidic solution provided with the kit; the photometric
absorbance of the dyed solution is directly proportional to
the amount of collagen in the sample.
For our study, HTF cells from all seven cell lines were
seeded into three 25 cm2 culture flasks each and allowed to
grow to 90% confluence. The culture medium used differed
from the medium in all other experiments, in that it was
supplemented with only 2% FCS, so as not to interfere with
the sircol dye. Upon reaching near-confluence, cell culture
medium was removed, cells were washed with PBS, and
1 ml of culture medium was added back to each of three
flasks from each cell line. Two of the flasks received 1 ml
of medium containing paclitaxel (10−9 mol/l to 10−6 mol/l),
the control received medium-containing vehicle only (0.1%
ethanol). After 1 hour of incubation, the medium from one
of the paclitaxel-containing flasks was again removed, cells
were washed again with PBS, and 1 ml of medium plus
vehicle were added. After 72 hours of further incubation,
medium was collected from all flasks, cell debris removed
from the samples by centrifugation (500 g for 5 min), and
collagen concentration was determined as described above.
Since we used only the culture medium for our measure-
ments, only the concentration of the soluble collagen—
which had been released from the cells and did not have
time to crosslink into larger structures—was determined,
thus giving an estimate of the current rate of collagen
production of the cells. In order to adjust for anti-
proliferative or cytotoxic effects of paclitaxel, the treated
cells were detached and counted, and collagen concentra-
tion was expressed as relative to control.
Flow cytometry
The rate of apoptosis and necrosis of the cells were determined
by flow cytometry (FACSCalibur, BD Heidelberg, Germany)
using dual stainingwith annexin V-FITC and propidium iodide
(Annexin-FLUOS staining kit, Roche Diagnostics, Germany)
as described by Crowston et al. [19]. Measurements were
performed in three of the seven cell lines (HTF-4, 6, and 7,
randomly chosen) at three different time points (24, 96, and
168 hours after initial exposure to Paclitaxel). At these time
points, culture medium and PBS rinsing solution (potentially
containing dead cells) were collected and joined with the cell
suspension obtained through trypsination of each sample. The
cells were pelleted through centrifugation (1000 rpm for
5 min at room temperature), and then resuspended in 100 µl
PBS. This cell suspension was added to 100 µl of buffer
containing 2 µl each of FITC-labelled annexin V and
propidium iodide, and allowed to incubate for 15 min in the
dark. During this time, annexin V binds to phosphatidyl-
serine that is exposed in the cell membranes of both
necrotic and apoptotic cells but inaccessible in viable
cells. Propidium iodide cannot permeate the otherwise
intact cell membrane of apoptotic cells, but enters
necrotic cells and intercalates in the nuclear DNA of
these cells. Thus, by plotting fluorescence intensity of
annexin V-FITC (detection wavelength: 530 nm, FL-1) vs
propidium iodide (650 nm), apoptotic cells can be
distinguished from viable and necrotic cells. Analysis of
the obtained data was performed using the BD Software
CellQuest Pro (v4.0.1).
Statistical analysis
Unless stated otherwise, all results are expressed as mean ±
standard error of the mean. Following the methods
described by Ludbrook [20], we employed repeated
measures ANOVA for the growth and scratch-migration
assays as well as the flow-cytometric measurements, in
order to determine differences in the effects of the various
concentrations of paclitaxel. For the collagen assays, two
way ANOVA with post hoc tests for differences between
the various concentrations and exposure times were used.
Global significance was assumed at p<0.05; local levels of
significance were adjusted using the Greenhouse–Geisser
method to correct for sample asphericity—which necessar-
ily occurs in this type of experimental set-up (proliferation
and migration assays)—or the Bonferroni correction for
multiple testing (collagen assay). All analyses were per-
formed using SPSS 17 Advanced Module (SPSS Inc.).
Results
Proliferation
There was a dose-dependent decrease in cell growth for
HTF cells exposed to paclitaxel for 1 hour compared to
control, which was significant at all tested doses. As shown
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in Fig. 1, relative cell count on day 7 of the observation was
355.9±30.1% in the control vs 212.4±24.5% (p<0.004),
187.3±17.2% (p<0.001), 101.4±5.4% (p<0.003), and
72.7±4.5% (p<0.001) in the cells treated with paclitaxel
10−9 mol/l, 10−8 mol/l, 10−7 mol/l, and 10−6 mol/l respec-
tively. Continuous exposure to paclitaxel did not only
abolish growth of the cells but also led to a significant dose-
dependent cell loss. Relative cell count increased in
untreated cells to 774.4±113.4%, but decreased to 43.2±
14.7% (p<0.014), 30.6±6.6% (p<0.016), 20.6±5.3%
(p<0.013) and 13.8±4.9% (p<0.001) in the cells treated
with 10−9 mol/l, 10−8 mol/l, 10−7 mol/l, and 10−6 mol/l of
paclitaxel (see Fig. 2). Although there was a trend toward a
decreasing cell count with increasing concentrations of
paclitaxel, no significant difference between any of the
treatment groups with continuous exposure could be
detected.
Scratch-migration assays
Figures 3 and 4 depict the development of the width of the
scratch prepared in confluent monolayers of HTF cells as
described above over the course of 1 week. In cells exposed
to paclitaxel for only 1 hour, there was a trend toward
slower closure of the cell-free gap. This difference was
statistically significant in all but one concentration
(10−8 mol/l). The hypothesis of equality of all groups was
rejected on the basis of a global p-value of <0.001, with
p<0.003 (10−9 mol/l), p=0.076 (10−8 mol/l), p<0.004
(10−7 mol/l), and p<0.002 (10−6 mol/l) for post-hoc
comparisons between control and each of the concentra-
tions. On day 7, there was a mean width of 38.8±14.1 µm
in the 10−6 mol/l group, whereas in the control and the cells
treated with 10−9 mol/l, 10−8 mol/l, and 10−7 mol/l of
paclitaxel the gap had closed on days 2, 3, 4 and 6
respectively. A more prominent effect was observed after
continuous treatment of the cells with paclitaxel. While in
the wells treated with vehicle alone the scratch had closed
after 2 days, there still remained a cell-free area with a
mean width of 34.1±29.9 µm for 10−9 mol/l (p=0.142,
not significant), 20.4±16.6 µm for 10−8 mol/l (p=0.039),
77.2±28.4 µm for 10−7 mol/l (p=0.006) and 391.7±
70.9 µm for 10−6 mol/l (p<0.001) of paclitaxel on day 7
of the observation. A sample photograph for untreated
(Fig. 5a and b) and treated (Fig. 5c and d) cells
immediately after and 48 h after the scratch is shown in
Fig. 5. The morphological changes in the cells observed at
higher concentrations of paclitaxel can also be assessed in
this microphotograph (Fig. 5d).
Collagen assays
Medium samples taken 72 hours after treatment with
vehicle (control) or paclitaxel for either 1 hour or 72 hours
revealed a slight, but statistically significant decrease in





























Fig. 1 Relative HTF cell count
over a course of 7 days after
exposure of the cells to different
concentrations of paclitaxel for
1 hour
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exposure to paclitaxel, the relative concentration compared
to control of soluble collagen was reduced to 71.7±8.0%
(p=0.006), 79.0±4.0% (p<0.001), 86.7±4.0% (p=0.005)
and 82.9±5.4% (p=0.011) for treatment concentrations of
10−6 mol/l, 10−7 mol/l, 10−8 mol/l and 10−9 mol/l. In the
cells treated continuously for 72 hours, collagen concen-
tration dropped to 70.7±7.4% (p=0.004), 73.5±12.1%
(p=0.041), 69.4±8.5% (p=0.003) and 77.1±6.2% (p=
0.005) respectively. Interestingly, there was no statistical
difference between any of the various concentrations of
paclitaxel nor between exposure times (Fig. 6).
Flow cytometry
The mean rate of apoptosis increased in a dose- and time-
dependent fashion to 22.5±8.1% on day 7 for cells exposed
to 10−6 mol/l of paclitaxel for 1 hour. Rate of apoptosis was

























Paclitaxel 10-9 M Paclitaxel 10-8 M Paclitaxel 10-7 M Paclitaxel 10-6 M Control
*
Fig. 2 Relative HTF cell count
over a course of 6 days with
continuous exposure of the cells






























Fig. 3 A cell-free area was
introduced by scratching a
pipette tip through a confluent
monolayer of HTF cells. The
absolute width of this scratch
after treatment of the cells with
different concentrations of
paclitaxel for 1 hour was
observed over a period of
7 days






























Fig. 4 Absolute width of the
cell-free area during 1 week of
continuous treatment of the cells













Fig. 5 Sample photographs of cells immediately after introducing an
approximately 600 µm-wide scratch in a confluent monolayer of
cells (a, c), and 48 hours later, after continuous treatment with
10−6 mol/l paclitaxel (d) or vehicle (b). In the “untreated” control the
gap has closed with only a few remaining cell-free areas, whereas in
the treated dish, the gap is virtually unchanged. Noteworthy are the
morphologic changes in the treated cells, which are seen at
concentrations exceeding 10−7 mol/l of paclitaxel (d)
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10−8 mol/l and 10−9 mol/l respectively. Continuous expo-
sure to paclitaxel led to apoptosis rates of 23.7±7.2%,
17.3±7.9%, 9.9±3.0%, and 2.4±1.0% for 10−6 mol/l,
10−7 mol/l, 10−8 mol/l and 10−9 mol/l. (Fig. 7a,b). The rate
of necrotic cells remained very low and relatively stable
over the entire observation period. It was highest in the
samples continuously exposed to higher concentration of
paclitaxel (Fig. 7c,d). Because of large variability between
individual cell lines, and because only three of the seven





































































Control Paclitaxel 10-6 M Paclitaxel 10-7 M Paclitaxel 10-8 M Paclitaxel 10-9 M
dc
a



























Paclitaxel 10-6 M Paclitaxel 10-7 M Paclitaxel 10-8 M Paclitaxel 10-9 M
*
*  
n. s. d. (p=0.235)
(p<0.001)
(p<0.001)Fig. 6 Relative concentration of
soluble collagen in the culture
medium of untreated control and
cells exposed to either 1 hour or
72 hours of paclitaxel at differ-
ent concentrations. The treated
cells produce significantly less
collagen than the control cells;
however, no difference was
found between different
concentrations of paclitaxel or
different treatment times
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between the treatment concentrations did not reach global
statistical significance.
Discussion
Scarring of the Tenon's capsule and to a lesser extent of the
scleral flap present the most prominent challenge to
filtering glaucoma surgery. While the use of mitomycin C
has greatly improved the success rate of this type of
intervention, the associated failure rate of up to 45% at
5 years postoperatively remains high [21, 22]. Repeated
adjunctive injections of 5-FU as well as secondary
procedures (e.g. needlings) are quite common, but yield
only limited success. In addition, the most commonly used
anti-proliferative substances have shown detrimental effects
and complications such as choroidal detachment, hypotony,
bleb leakage or blebitis, as well as cell loss of the corneal
epithelium and endothelium, often leading to further,
potentially permanent impairment of vision [23, 24]. This
may be a direct result of applying relatively high (and
potentially toxic) doses of these substances for a very brief
time. A potentially less toxic alternative could be the
extended exposure of the filtering bleb to much lower doses
of anti-fibrotic drugs.
Glaucoma drainage devices pose the unique opportunity
of introducing a slow-release mechanism for low concen-
trations of anti-proliferative substances directly to the site
of scar formation in filtering surgery. In animal models,
several successful attempts have been made to improve the
outcome of conventional filtering surgery by inserting drug-
eluting devices into the filtering bleb. Hydrogels as well as
bio-degradable polymers have been used to incorporate a
range of anti-proliferative substances in these animal
studies [25–28].
In our study we investigated the effects of paclitaxel, a
substance already used in drug-eluting coronary stents, on
primary cultures of human Tenon's fibroblasts. Our results
show that both short- and long-term exposure to low doses
of paclitaxel inhibit growth and migration of the cells in a
dose-dependent fashion. There were marked differences
between the two exposure times, however. While the
fibroblasts tolerated concentrations of paclitaxel as high as
10−7 mol/l for 1 hour (cell proliferation was completely
abolished at this concentration, see Fig. 1), the long-term
exposure of the cells to even the low concentration of
10−9 mol/l led to a significant decrease in cell count. Thus,
a brief exposure of the scleral flap and conjunctiva to the
compound during glaucoma surgery—similar to that of
MMC—may be a suitable procedure for the application of
higher concentrations of paclitaxel. On the other hand,
concentrations even lower than the ones tested in our study
may be sufficient to suppress scar formation by an extended
release mechanism. As shown in animal studies, the long-
term exposure to paclitaxel can be effective in preventing
bleb scarring after filtering surgery [25, 26]. More recently,
Koz et al. showed that the slow elution of paclitaxel from
hydrogels in rabbit eyes performed equally as well as MMC
administered in the traditional fashion with respect to
inflammatory response and fibrosis [27]. In a similar
approach, Polak et al. showed that slow release of other
anti-proliferative substances such as the anti-metabolites
5-fluorouracil (5-FU) and 5-chlorouracil (5-CU) from
polymers implanted after filtering surgery has beneficial
effects on long-term bleb development and intraocular
pressure [28].
The effect of paclitaxel on HTF cell migration in our
study was far less pronounced. Even though the effects
were statistically significant already at low concentrations
and brief exposure, only the long-term administration of
the drug led to a biologically relevant decrease in cell
migration (see Figs. 3 and 4). A study performed on rabbit
Tenon's fibroblasts yielded similar results: in this investi-
gation, the relatively high concentration of 10−6 mol/l of
paclitaxel was necessary to significantly inhibit TF cell
migration [29].
Our investigation also showed a decrease in collagen
release into the culture medium following the administra-
tion of paclitaxel. However, there was no correlation
between the measured collagen concentration and the
applied dose or exposure time in our study. One possible
explanation could be that there may be no direct effect of
paclitaxel on collagen synthesis. Human Tenon's fibroblasts
are known to release TGF-beta1 [30], a growth factor that
stimulates collagen synthesis in these cells [31–33].
Paclitaxel has been shown to interfere with TGF-beta
signaling [16, 17]. In our study, paclitaxel may have
abolished the autocrine effects of TGF-beta1 released by
the Tenon's fibroblasts themselves at all applied concen-
trations, thus reducing collagen production to a constitutive
level. However, this remains speculative and further
investigation is needed.
Since higher concentrations of paclitaxel led to changes
in morphology of the cells (Fig. 5d), the question was
raised whether cytotoxic effects may have been responsible
for the lower cell count and decreased migratory activity
observed. By assessing the rate of both apoptosis and
necrosis, we were able to determine that paclitaxel does
indeed lead to cell death in a dose-dependent fashion.
However, the number of necrotic cells (as an indicator for
direct toxicity) was relatively low in all samples, with the
highest observed rate at 6.5% of the cells on day 4 of the
samples continuously treated with 10−6 mol/l of paclitaxel.
By comparison, rates of necrosis as high as 9.4% have been
reported for MMC after 5-minute exposure at a clinically
used concentration [19].
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Apoptosis appears to play a more prominent role, and is
much more likely to have influenced the final number of
cells in our experimental setting (Fig. 7). The apoptosis rate
at the highest concentration in our study was lower than
that of MMC as reported by Crowston et al., who saw 32%
apoptosis already at 48 hours [34], thus indicating that
induction of apoptosis may also play a prominent role in the
inhibition of bleb failure through use of MMC. In general,
side-effects of paclitaxel should be similar in nature to those
seen in MMC, as both compounds arrest the cell cycle.
While paclitaxel interferes with the mitotic spindle, MMC’s
effects may be broader, because it intercalates in DNA and
thereby probably does not only interfere with DNA
replication but also with transcription and protein synthesis.
Interestingly, in our study the rate of apoptosis was very
similar between brief and long-term exposure, which
contrasts the observed differences in the growth rates
between the applied concentrations. Thus, while cell death
certainly influenced our growth and migration assays, it
cannot fully explain the differences between the exposure
times. Inhibition of proliferation by cell cycle arrest through
stabilization of microtubules may be independent of—or
start at lower concentrations than—induction of apoptosis.
The concentrations used in our study were lower than the
systemic concentrations reached in oncological patients
undergoing chemotherapy. A typical dose for ovarian
cancer is 175 mg per m2 of body surface [35]. This
corresponds to approximately 5 x 10−6mol/l in the
extracellular fluid. The total dose of paclitaxel in coronary
stents does not usually exceed 3 µg per mm2 of contact
area, and should not cause any systemic effects even if
released instantaneously. Similarly, a coated GDD would
not be very likely to cause systemic side-effects. Stability of
paclitaxel in aqueous solutions is of some concern, as the
compound is most stable at acidic pH, and hydrolyses at
neutral pH [36]. This is overcome in coronary stents by
embedding the compound into biodegradable polymer
coatings that control the release of the substance and
thereby its exposure to the aqueous environment [37].
In conclusion, our study represents the first in vitro
investigation of the effects of paclitaxel on primary cultures
of human Tenon's fibroblasts. Our results indicate that
paclitaxel may be an interesting candidate drug for the
prevention of bleb scarring after filtering glaucoma surgery.
Both short- and long-term exposure of human Tenon's
fibroblasts to the compound resulted in a dose-dependent
inhibition of proliferation and migration of the cells, with
cytotoxic effects comparable to those of MMC. A biphasic
release of paclitaxel from a glaucoma drainage device or a
biodegradable spacer with a short initial peak, followed by
a continuous elution of very low concentrations, may be an
interesting mechanism for this substance. While MMC is
firmly established in ophthalmology, paclitaxel may be
advantageous in terms of development of a suitable coating
for a drug-releasing device, due to years of experience with
coated coronary stents. For this purpose, however, further
investigations are needed to determine the compound's
effects on the expression and release of collagen and other
extracellular matrix components.
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